MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Fabry Disease
Related studies linked through entity extraction aliases.
Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry Disease
- Status
- COMPLETED
- Phase
- NA
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
- Status
- COMPLETED
- Phase
- PHASE3
Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients
- Status
- UNKNOWN
- Phase
- N/A
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE3
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
- Status
- COMPLETED
- Phase
- PHASE3
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
- Status
- COMPLETED
- Phase
- PHASE3
Evaluation of HEArt invoLvement in Patients With FABRY Disease
- Status
- RECRUITING
- Phase
- N/A
Kidney Information Network for Disease Research and Education
- Status
- TERMINATED
- Phase
- N/A
Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Fabry Outcome Survey (FOS)
- Status
- COMPLETED
- Phase
- N/A
Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy
- Status
- UNKNOWN
- Phase
- N/A
Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy
- Status
- COMPLETED
- Phase
- N/A
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases
- Status
- UNKNOWN
- Phase
- N/A
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
- Status
- COMPLETED
- Phase
- PHASE3
Evaluation of Phenotypic Variability in Fabry Disease
- Status
- WITHDRAWN
- Phase
- N/A
German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.
- Status
- COMPLETED
- Phase
- N/A
Study of the Relation Between Lipid Myocardial Overload Evaluated by Cardiac Magnetic Resonance Imaging (MRI), Alteration of Longitudinal Myocardial Deformations by Echocardiography, and Clinical Achievements (Functional, Biological and Electrical) in Fabry Disease, and Its Outcomes.
- Status
- UNKNOWN
- Phase
- N/A